Competitive advantages of Phylomer^® peptides over other biologics derived from natural sequences

Phylomer^® peptides have a clear competitive advantages over other biologics derived from natural sequences. These include:

• More biodiversity than biologics sourced from eukaryotes – Phylomers^® are sourced from microbes (Bacteria and Archaea) i.e. biological genomes that are not human in origin. This feature can enhance the potential to isolate high potency peptides against human protein targets, as the affinities of Phylomers^® binding similar targets can exceed the affinities of peptides derived from the target interfaces themselves.
• Broad freedom-to-operate – the non-human origin of the Phylomer^® sequences means they have rarely been patented, allowing access to multiple high value targets.
• Reduced probability of immunogenic T-cell epitopes that could result in unintended immune reaction – while the origin of Phylomers^® might result in an increased potential for immunogenicity issues, the typical 15 to 50 amino acids size of Phylomers^® significantly reduces the probability of them containing immunogenic T-cell epitope. This is in contrasts to larger foreign proteins which are almost always immunogenic. In animal vaccination studies and in human T-cell proliferation assays, Phylogica has found no evidence suggesting that Phylomer^® peptides are particularly immunogenic when compared to equivalently sized biologics from alternative sources.
• Better fit (affinity) than peptides derived from natural target interface – Phylomers^® are capable of higher affinity binding than peptides derived from the natural target interface, due to evolution selecting for intermediate affinities of interaction between proteins sourced from the same host species. In contrast, Phylomer^® peptides have not been subjected to this evolutionary constraint and therefore can bind these target surfaces with higher affinity.